CN1702068A - Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist - Google Patents

Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist Download PDF

Info

Publication number
CN1702068A
CN1702068A CNA2004100425722A CN200410042572A CN1702068A CN 1702068 A CN1702068 A CN 1702068A CN A2004100425722 A CNA2004100425722 A CN A2004100425722A CN 200410042572 A CN200410042572 A CN 200410042572A CN 1702068 A CN1702068 A CN 1702068A
Authority
CN
China
Prior art keywords
phenyl
methyl
propionic acid
oxazole
oxyethyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004100425722A
Other languages
Chinese (zh)
Other versions
CN100436430C (en
Inventor
李松
周辛波
林翠芳
王莉莉
徐成
阮承迈
肖军海
郑志兵
刘洪英
谢云德
钟武
崔浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Muolike Science and Technology Co., Ltd.
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CNB2004100425722A priority Critical patent/CN100436430C/en
Priority to PCT/CN2005/000147 priority patent/WO2005115998A1/en
Publication of CN1702068A publication Critical patent/CN1702068A/en
Application granted granted Critical
Publication of CN100436430C publication Critical patent/CN100436430C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to general formula I compound, substituent definition of which is discussed in requirement of right, its racemic unit, optical isomer or medicament containing the compound. The invention also relates to its process for preparing and usage in treatment of hyperglycemia, lipidosis and so on.

Description

The tyrosine derivative that replaces as the alkyloyl of hPPAR α and hPPAR gamma agonist
Technical field
The present invention relates to tyrosine derivative or its pharmacy acceptable salt or solvate, their preparation method, contain they pharmaceutical composition and they be used for the treatment of as the agonist of peroxisome proliferator-activated acceptor (be called for short PPAR), the dual agonists that especially PPAR γ and PPAR α demonstrated agonism and/or the purposes of metabolism diseases such as prevent diabetes and hyperlipidaemia.
Background technology
Peroxisome proliferator-activated acceptor (abbreviating PPAR as) is the ligand-dependent type transcription factor that belongs to the intranuclear receptor superfamily with glucocorticoid receptor, retinoid receptor and pth receptor etc.Up to now, it has been found that three kinds of PPAR hypotype: α, γ and δ (also claiming β and NUC1).They are by different genes encodings.And also there are 2 kinds of isoform PPAR γ in PPAR γ 1And γ 2These 2 kinds of proteinic differences are their NH 2-30 terminal amino acid, they are results (Vidal-Puig, J.Clin.Invest., 97:2553-2561,1996) with the difference montage of nRNA of being used alternatingly of promotor.
PPAR α mainly expresses in the tissue that lipid is had high catabolic activity such as brown adipose tissue and liver, secondly is in kidney, heart, skeletal muscle.(Endocnnology，1995，137，354)。Carry relevant gene (for example acyl-CoA synthetic enzyme, fatty acid binding protein matter and lipoprotein lipase) and the lipophorin (AI relevant in its energy positive regulation or negative control and fatty acid metabolism and the born of the same parents with the metabolism of cholesterol and neutral lipid; AII, CIII) expression of gene.PPAR γ mainly is present in the fatty tissue, also is present on a small quantity in skeletal muscle, liver, colon, retina, the immunity system.Result of study also points out it highly to be expressed in scavenger cell recently, comprises in the atherosclerotic foam cell.Wherein, PPAR γ 2Main specificity expression in fatty tissue, and PPAR γ 1Discovery is then all arranged in various tissues, wherein express the highest at kidney, intestines and heart.PPAR γ mainly regulates and relates to adipocyte differentiation and insulin sensitivity expression of gene (J.Lipid.Res., 1996,37,907).
PPAR δ is that generally express in each tissue in vivo at the center with the neurocyte.At present, not clear about the physiologic meaning of PPAR δ.
Thiazolidinediones medicine such as troglitazone, rosiglitazone show the insulin action that can strengthen the type ii diabetes patient clinically, reduce serum glucose.Reported that thiazolidinedione is effectively and the optionally activator of PPAR γ, and directly be attached to PPAR γ acceptor (J.M.Lehmann etc., J.Biol.Chem.12953-12956,270 (1995)).
Special class (fibrates) medicine one of shellfish can reduce serum triglyceride (20-50%), LDL (10-15%) to the curative that is widely used as hyperlipidaemia, and increases HDL (10-15%).Experiment shows, fibrates is activation mediation by PPAR α to the effect of serum lipid, for example can referring to, B.Staels etc., Curr.Pharm.Des., 1-14,3 (1), (1997).The activation of PPAR α causes increases transcribing of lipid acid katabolism and the enzyme that reduces lipid acid synthetic once more (causing the synthetic and VLDL generation/secretion minimizing of triglyceride level) in the liver.In addition, PPAR α activates the generation that reduces apoC-III.The minimizing that apoC-III (the active inhibitor of LPL) produces has increased the removing (J.Auwerx etc., Atherosclerosis, J59-S37,124 (Suppl), (1996)) of VLDL.
The result of study of prior art shows, have to the medicine of the double excitations effect of PPAR γ and PPAR α reduce diabetes with other triglyceride level that unusually, especially raise in can have additional benefits, for example can be referring to US5478852, WO98/05331.
Summary of the invention
The objective of the invention is to seek and develop the micromolecular compound with PPAR γ and PPAR α agonist activity, described compound can be used to treat hPPAR γ and/or alpha mediated disease, risk factor or the illness of hPPAR.The inventor finds that after deliberation the compound of following general formula I has PPAR γ and PPAR α agonist activity, thereby can be used for preventing and/or treating and PPAR γ and PPAR α diseases associated or symptom, as diabetes or hyperglycemia.The present invention finds that further compound of Formula I also has good reducing blood lipid.
Therefore, an aspect of of the present present invention relates to formula I compound, its raceme, optically active isomer or its pharmacy acceptable salt or solvate,
Wherein:
R 1And R 2Be selected from H independently of one another, C 1-C 4The straight or branched alkyl;
Ar is selected from aromatic carbocyclic or heterocycle, and ring wherein is monocycle, dicyclo or three rings; Each ring is 5-6 unit ring, comprises in the heterocycle that 1-4 is selected from following heteroatoms: O, S, N; Do not have on the ring to replace or be selected from following substituting group and replace: halogen, nitro, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, C by 1-5 1-C 6The straight or branched alkyl, C 2-C 6The straight or branched thiazolinyl, C 1-C 4Alkoxyl group, C 2-C 4Alkenyloxy, phenoxy group, benzyloxy, carboxyl or amino;
Y is H, halogen;
N is the integer of 1-4;
M is 0 or 1,
X is CH 2, O, S,
Figure A20041004257200112
Group.
Another aspect of the present invention relates to the pharmaceutical composition that comprises The compounds of this invention, and it contains raceme or optically active isomer or its pharmacy acceptable salt or solvate and one or more pharmaceutical carrier or the vehicle of at least a compound of Formula I.
Another aspect of the present invention relates to the method for preparing compound of Formula I or its pharmacy acceptable salt or solvate.
Another aspect of the present invention relates to the intermediate of preparation compound of Formula I or its pharmacy acceptable salt or solvate.
Of the present inventionly relate in one aspect to the purposes that compound of Formula I of the present invention is used to prepare the medicine of treatment or prevention hPPAR γ and/or hPPAR alpha mediated disease, risk factor or illness again.
Described hPPAR γ and/or the alpha mediated disease of hPPAR, risk factor or illness comprise hyperglycemia, the lipoidosis lipidemia, type ii diabetes comprises relevant diabetic lipoidosis lipidemia, type i diabetes, hypertriglyceridemia, X syndrome, insulin resistance, in heart failure, hyperlipidaemia, hypercholesterolemia, hypertension, cardiovascular disorder comprises atherosclerosis and suffers from as obesity, apositia, the appetite of exessive appetite and patients with anorexia nervosa and the adjusting of food absorption.
Specifically, in one embodiment of the invention, the present invention relates to compound of Formula I, its raceme, optically active isomer or its pharmacy acceptable salt or solvate,
Figure A20041004257200121
Wherein:
R 1And R 2Be selected from H independently of one another, C 1-C 4The straight or branched alkyl;
Ar is selected from aromatic carbocyclic or heterocycle, and ring wherein is monocycle, dicyclo or three rings; Each ring is 5-6 unit ring, comprises in the heterocycle that 1-4 is selected from following heteroatoms: O, S, N; Do not have on the ring to replace or be selected from following substituting group and replace: halogen, nitro, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, C by 1-5 1-C 6The straight or branched alkyl, C 2-C 6The straight or branched thiazolinyl, C 1-C 4Alkoxyl group, C 2-C 4Alkenyloxy, phenoxy group, benzyloxy, carboxyl or amino;
Y is H, halogen;
N is the integer of 1-4;
M is 0 or 1,
X is CH 2, O, S, Group.
In a preferred embodiment of the invention, compound of Formula I is the S configurational isomer of general formula I I representative, or its pharmacy acceptable salt or solvate,
Wherein:
Be connected in COOR 1Carbon atom be the S configuration;
R 1And R 2Be selected from H independently of one another, CH 3
Ar is selected from aromatic carbocyclic or heterocycle, and ring wherein is for being monocycle, dicyclo or three rings; Each ring is 5-6 unit ring, comprises in the heterocycle that 1-4 is selected from following heteroatoms: O, S, N; Do not have on the ring to replace or be selected from following substituting group and replace: halogen, nitro, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, C by 1-5 1-C 6The straight or branched alkyl, C 2-C 6The straight or branched thiazolinyl, C 1-C 4Alkoxyl group, C 2-C 4Alkenyloxy, phenoxy group, benzyloxy, carboxyl or amino;
Y is H, Br;
N is the integer of 1-4;
M is 0 or 1,
X is CH 2, O, S, Group.
Preferred The compounds of this invention and corresponding chemical structure thereof are as follows:
Figure A20041004257200141
Figure A20041004257200171
Figure A20041004257200211
Figure A20041004257200231
Compound of Formula I of the present invention or its pharmaceutical salts or solvate,
R wherein 1, R 2, Ar, X, Y, m, the same general formula I of the definition of n,
Can be by the formula III compound
Y wherein, n, R 1The same general formula I of definition, Ph is a phenyl;
React with formula X compound and to obtain,
Ar wherein, X, R 2, the same general formula I of the definition of m.
One of raw material of above-mentioned reaction formula III compound can prepare by the following method:
1) reacted by commercially available benzamide that gets and formula IV compound, cyclization obtains formula V compound.Formula V compound is again through tetrahydrochysene lithium aluminium (LiAlH 4) reduction, obtain formula VI compound.The preparation of formula IV compound wherein can be referring to Chem.Phar.Bull. (1986), 34 (7), 2840-51; J.Med.Chem. (1992), 35 (14), 2617-26.
2) make the formula VII compound of the definition of wherein Y and n with general formula I, especially preferably wherein Y=H or n=1, Y=Br and Br are positioned at hydroxyl adjacent formula VII compound elder generation and R 1OH (R wherein 1The same general formula I of definition, preferred R 1=CH 3), thionyl chloride reaction, then and BOC 2O reacts, and obtains the compound of VIII, wherein, and R 1, the same general formula I of the definition of Y and n.Described n=1, Y=Br and Br are positioned at hydroxyl adjacent formula VII compound and can be made by tyrosine and bromine reaction,
Figure A20041004257200242
3) the formula VIII compound reaction that formula VI compound and the step 2 that step 1) is obtained) obtains obtains wherein Y, n and R 1Definition with the formula IX compound of general formula I,
Figure A20041004257200243
Then make formula IX compound with trifluoroacetic acid deprotection base, promptly obtain wherein Y, n and R 1Definition with the formula III compound of general formula I,
With regard to another raw material formula X compound, for the compound of m=0 in the general formula I or X=C, it can be by commercially available acquisition; For the compound of X=O in the general formula I or S, they can be by commercially available acquisition or reference literature (Patel, V.F., Andis, S, Li, et al, J Org Chem1997,62 (25): 8868-8874; D ' Arcangelis, Samuel T, Cowan, Dwaine O, Tetrahedron letter, 1996,37 (17): 2931-2934) reported method preparation; For X=in the general formula I
Figure A20041004257200252
Compound, its can by commercially available acquisition or by the compound of X=S according to ordinary method (see " and practical Minute Organic Synthesis handbook, Duan Hangxin compiles, Chemical Industry Press (2000) P385-386) makes.
If desired, compound of Formula I can change into the compound of Formula I of another kind of form, for example, and R 1=C 1-C 4The compound of Formula I of straight or branched alkyl obtains R under the effect of alkali metal hydroxide 1The compound of Formula I of=H.
More specifically, the building-up reactions scheme of compound of Formula I sees following reaction scheme and description for details:
Reactions steps one:
The compound of formula IV and benzamide (available from Beijing chemical reagents corporation) were reflux in toluene reaction 6-30 hour.Concentrate, post separates (eluent:, obtain brown buttery formula V compound the n-hexane/ethyl acetate system).Formula V compound and tetrahydrochysene lithium aluminium (LiAlH 4, available from Tianjin ring prestige Fine Chemical Co., Ltd) under the room temperature in ether, mix and stirred 1-24 hour.Carefully dripping water, aqueous sodium hydroxide solution and anhydrous magnesium sulfate successively stirred 0.1-1 hour.Filter, filtrate concentrates, and post separates (eluent:, obtain the compound of the formula VI of white solid the n-hexane/ethyl acetate system).Here employed silica gel is conventional column chromatography silica gel, granularity 10-40 μ m.Obtain compound VI behind the purifying.
Reactions steps two:
Y wherein, n, R 1The same general formula I of definition.
The compound of formula VII, preferred especially Y=H or n=1, Y=Br and Br are positioned at hydroxyl adjacent formula VII compound elder generation and R 1OH (preferred R 1=CH 3), thionyl chloride mixing backflow 1-10 hour, concentrate.The residue that obtains is followed and BOC 2O in the triethylamine under the catalysis, stirring at room 1-8 hour, concentrates in anhydrous acetonitrile.The dissolving that adds methylene chloride is washed drying with streamer acid hydrogen sodium water solution, saturated aqueous sodium carbonate, saturated sodium-chloride water solution successively.Concentrate, the ether recrystallization obtains the compound of the formula VIII of white solid.The compound of the formula VII of n=1, Y=Br (Br is positioned at the hydroxyl ortho position) wherein, can by tyrosine and bromine in Glacial acetic acid-a 20-110 ℃ reaction made in 0.5-48 hour.Y, n are with the definition of general formula I.
Reactions steps three:
Y wherein, n, R 1The same general formula I of definition.
Compound VI and formula compound VIII in organic solvent such as THF, under-20 ℃-150 ℃ (as 20 ℃) temperature, in the presence of triphenyl phosphine and azodicarboxylate such as diethylazodicarboxylate, are pressed Mitsunobu type method reaction 1-40 hour.Concentrate, again through silica gel column chromatography (eluent:, obtain Compound I X the n-hexane/ethyl acetate system).Compound I X and trifluoroacetic acid in organic solvent such as methylene dichloride-20 ℃-40 ℃ the reaction 1-40 hour.Reaction solution neutralizes with aqueous sodium hydroxide solution, the organic layer drying.Concentrate, the crude product that obtains is through silica gel column chromatography (eluent:, obtain compound III the chloroform/methanol system).
Reactions steps four:
Y wherein, n, R 1, R 2, the same general formula I of the definition of m, x and Ar.
With compound III and compounds X at non-polar solvent, for example in the methylene dichloride, reacted 0.1-20 hour in the presence of nothing or dewatering agent such as DCC or CDI in room temperature, perhaps earlier the formula III compound was reacted 0.5-10 hour with thionyl chloride 0-80 ℃, after concentrating with the residue that obtains under-20-40 ℃, reaction 0.1-20 hour under the triethylamine catalysis in non-protonic solvent such as methylene dichloride.To react reaction solution washing, the drying, concentrated that obtains as stated above, the crude product that obtains is through silica gel column chromatography (eluent:, promptly obtain Compound I the petrol ether/ethyl acetate system).
If desired, compound of Formula I can change into the compound of the general formula I of another kind of form, as R 1=C 1-C 4The compound of Formula I of the alkyl of straight or branched room temperature or back flow reaction 0.1-40 hour under the effect of alkali metal hydroxide obtain R through aftertreatment 1The compound of Formula I of=H.
Those skilled in the art will recognize that there is three-dimensional center in formula I compound of the present invention.When needs formula I compound is single enantiomorph, can use the reactant that in all possible step, all is in single enantiomeric forms to prepare, perhaps in the presence of the reagent of single enantiomeric forms or catalyzer, react and prepare, perhaps split stereoisomer mixture and prepare by ordinary method.Some preferable methods comprise uses microorganism to split, the salt of the diastereomer that any spendable acid such as fractionation and chiral acid such as amygdalic acid, camphorsulfonic acid, tartrate, lactic acid forms, the perhaps salt of the diastereomer of formation such as fractionation and chiral base such as brucine (bracine), Peruvian bark alkaloid and derivative thereof.Method commonly used is seen " Enantiomers, Racemates and Resolution " (WileyInterscience, 1981) that people such as Jaques edits.More specifically, the compound of formula I can be by handling 1: 1 the mixture that changes into the diastereo-isomerism acid amides with Chiral Amine, amino acid, by amino acid derived amino alcohol; Can use conventional reaction conditions that acid is changed into acid amides; Diastereomer can separate by fractional crystallization or chromatography, and the steric isomer of formula I compound can prepare by the pure diastereo-isomerism acid amides of hydrolysis.
According to the present invention, compound of Formula I can be used for treating or preventing hPPAR γ and/or alpha mediated disease, risk factor or the illness of hPPAR.Described hPPAR γ and/or the alpha mediated disease of hPPAR, risk factor or illness include hyperglycemia, the lipoidosis lipidemia, type ii diabetes comprises relevant diabetic lipoidosis lipidemia, type i diabetes, hypertriglyceridemia, X syndrome, insulin resistance, in heart failure, hyperlipidaemia, hypercholesterolemia, hypertension, cardiovascular disorder comprises atherosclerosis, suffer from as obesity, apositia, the appetite of exessive appetite and patients with anorexia nervosa and the adjusting of food absorption.The compounds of this invention is specially adapted to treat or prevent hyperglycemia, lipoidosis lipidemia, type ii diabetes to comprise relevant diabetic lipoidosis lipidemia.
The compounds of this invention both can itself also can its pharmacy acceptable salt or solvate forms use.The pharmaceutically receivable salt of formula I compound comprises and pharmaceutically acceptable mineral acid or organic acid or mineral alkali or the conventional salt of organic bases formation and the acid salt of quaternary ammonium.The example of suitable acid salt comprises with hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, fumaric acid, acetate, propionic acid, succsinic acid, oxyacetic acid, formic acid, lactic acid, toxilic acid, tartrate, citric acid, pounces on the salt that acid, propanedioic acid, hydroxymaleic acid, toluylic acid, L-glutamic acid, phenylformic acid, Whitfield's ointment, fumaric acid, toluenesulphonic acids, methylsulfonic acid, naphthalene-2-sulfonic acid, Phenylsulfonic acid, hydroxynaphthoic acid, hydroiodic acid HI, oxysuccinic acid, tannic acid etc. form.Other acid as oxalic acid, though itself be not pharmaceutically acceptable, can be used to prepare the salt as intermediate, to obtain The compounds of this invention and pharmacy acceptable salt thereof.The example of suitable base addition salt comprises and sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N, the salt that N '-dibenzyl-ethylenediamin, chloro PROCAINE HCL, PHARMA GRADE, choline, diethanolamine, quadrol, N-methylglucosamine and PROCAINE HCL, PHARMA GRADE form.When relating to The compounds of this invention herein, comprise formula I compound and pharmacy acceptable salt thereof or solvate.
The present invention also comprises the prodrug of The compounds of this invention, and this prodrug promptly carries out chemical conversion by metabolic process in vivo once administration, becomes to have active medicine.Usually, this class prodrug is the functional derivatives of The compounds of this invention, and it changes into the compound of required formula (1) in vivo easily.For example, at " Design Of Prodrugs ", H.Bund Saard, Elsevier edit and have described the ordinary method of selecting and prepare suitable prodrug derivant in (1985).
The present invention also comprises the active metabolite of The compounds of this invention.
The compounds of this invention both can be separately also can pharmaceutical composition form use.Pharmaceutical composition of the present invention comprises formula I compound of the present invention, its raceme, optically active isomer or its pharmacologically acceptable salt or solvate and one or more suitable pharmaceutically acceptable carrier of effective dose.Pharmaceutical carrier of the present invention includes but not limited to: ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein such as human serum albumin, buffer substance such as phosphoric acid salt, glycerine, Sorbic Acid, potassium sorbate, the partial glycerol ester mixture of saturated vegetable fatty acid, water, salt or ionogen, as protamine sulfate, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt, colloided silica, Magnesium Trisilicate, polyvinylpyrrolidone, cellulosic material, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, beeswax, lanolin.
The pharmaceutical composition of The compounds of this invention can be used with following any-mode: oral, spraying sucks, rectal application, nasal cavity applied medicine, the cheek medication, local application, non-enterally administer, as in subcutaneous, vein, intramuscular, intraperitoneal, the sheath, in the ventricle, in the breastbone and intracranial injection or input, or by the medication of a kind of outer planting reservoir.Wherein preferred oral, intraperitoneal or intravenous administration mode.
When medicine for oral use, The compounds of this invention can be made into oral acceptable dosage form arbitrarily, includes but not limited to tablet, capsule, the aqueous solution or aqeous suspension.Wherein, the carrier that tablet uses generally comprises lactose and W-Gum, also can add lubricant such as Magnesium Stearate in addition.The thinner that capsule preparations uses generally comprises lactose and dried corn starch.Aqueous suspension preparation then normally mixes use with activeconstituents with examples of suitable emulsifiers and suspension agent.If desired, also can add some sweeting agents, perfume compound or tinting material in the above oral preparations form.
When local medication, particularly treat local external application easy to reach and suffer from face or organ, during as eyes, skin or lower intestinal tract nervous system disease, can The compounds of this invention be made different local application's dosage forms, specify as follows according to different trouble faces or organ:
When the eye topical application, The compounds of this invention can be mixed with the dosage form of a kind of micronization suspension or solution, and the carrier that uses is the Sterile Saline of isoosmotic certain pH, wherein can add or not adding preservative agent such as zephiran chloride alkoxide.For eye usefulness, also compound can be made paste form such as vaseline paste.
When topical application, The compounds of this invention can be made into suitable ointment, lotion or creme dosage form, wherein activeconstituents is suspended or is dissolved in one or more carriers.The spendable carrier of ointment formulation includes but not limited to: mineral oil, Albolene, white vaseline, propylene glycol, polyoxyethylene, polyoxytrimethylene, emulsifying wax and water; The spendable carrier of lotion or creme includes but not limited to: mineral oil, and sorbitan monostearate, polysorbate60, the n-Hexadecane ester type waxes, cetene is fragrant and mellow, 2-Standamul G, benzyl alcohol and water.
The all right aseptic injection preparation form medication of The compounds of this invention comprises aseptic injection water or oil suspension or aseptic injectable solution.Wherein, spendable carrier and solvent comprise water, Ringer's solution and isotonic sodium chlorrde solution.In addition, the fixed oil of sterilization also can be used as solvent or suspension medium, as direactive glyceride or two glyceryl ester.
It may be noted that in addition, the using dosage of The compounds of this invention and using method depend on all multifactor, comprise activity intensity, Time of Administration, metabolic rate, the severity of illness and diagnosis and treatment doctor's the subjective judgement of patient's age, body weight, sex, natural health situation, nutritional status, compound.Preferred using dosage is between 0.01～100mg/kg body weight/day, and wherein optimal dosage is in the 5mg/kg-10mg/kg body weight/day.
Embodiment
The following examples are the preferred illustrative preferred versions of the present invention, and the present invention is not constituted any limitation.
Melting point compound is measured by RY-1 type fusing point instrument, and temperature is not calibrated. 1H NMR spectrum is measured by Bruker ARX 400 types or US Varian Ulity Inova 600 type nuclear magnetic resonance spectrometers.The FAB mass spectrum is measured by Zabspect high resolution magnetic mass spectrometer.
Preparation embodiment 1:2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-ethanol (intermediate 1)
With 4-bromo-3-oxygen-methyl valerate (23.2g, 0.11mol) and benzamide (20.1g 0.17mol) is dissolved in the 160mL toluene, and reflux is removed the water that dereaction generates with water trap, reacts 9 hours.Concentrate, with the crude product that obtains through silica gel column chromatography (normal hexane: ethyl acetate=6: 1), obtain 5.6g light brown oily 2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-methyl acetate, yield 22%.
(2.3g 10mmol) is dissolved in the 16mL ether, drops to LiAlH under 0 ℃ with 2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-methyl acetate 4(0.38g is 10mmol) among the suspension 4mL in ether.Stirred overnight at room temperature.Reaction solution carefully adds the 15%NaOH aqueous solution, 1.2mL water and one spoonful of anhydrous magnesium sulfate of 0.4mL water, 0.4mL successively.Filter, filtrate concentrates, and obtains 1.6g 2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-ethanol, and it is a faint yellow solid, yield 80%.
MS[M]+＝231.2m/e；
1H-NMR(400MHz，CDCl 3)δ7.99-7.78(m，2H)，7.43-7.42(m，3H)，3.94(t，2H)，2.74(t，2H)，2.34(s，3H)。
Preparation embodiment 2A:(2S)-2-t-butoxycarbonyl amino-3-(4-hydroxyl-phenyl)-methyl propionate (intermediate 2A)
Under 0 ℃, (8mL 0.11mmol) drops to and contains L-tyrosine (17.9g is in methyl alcohol 0.1mmol) (100mL) solution with thionyl chloride.Refluxed 3 hours.Concentrate.Add triethylamine (15mL), acetonitrile (150mL), drip BOC again 2O (23.3mL, 0.11mmol).Stirring at room 1.5 hours.Concentrate, (200mL) dissolving that adds methylene chloride is used the 1M sodium pyrosulfate aqueous solution (200mL), a small amount of saturated aqueous sodium carbonate and washing, the organic phase anhydrous magnesium sulfate drying successively.Concentrate, obtain (2S)-2-t-butoxycarbonyl amino-3-(4-hydroxyl-phenyl)-methyl propionate (26.0g, 90%), it is a white solid.
MS[M]+＝295.4m/e；
1H-NMR(400MHz，CDCl 3)δ6.98-6.90(m，2H)，6.78-6.73(m，2H)，4.60-4.50(m，1H)，3.70(s，3H)，3.08-2.93(m，2H)，1.45(s，9H)。
Preparation embodiment 2B:(2S)-3-(3-bromo-4-hydroxyl-phenyl)-2-t-butoxycarbonyl amino-methyl propionate (intermediate 2B)
Under 0 ℃, will contain bromine (0.9g, glacial acetic acid solution 5.5mmol) (8mL) drop to L-tyrosine (1.0g, 5.5mmol) with the muddy liquid (10mL) of Glacial acetic acid in.Ambient temperature overnight.Filter, the oven dry filter cake obtains the 1.7g yellow solid, is directly used in next step reaction.
React according to method described in the above-mentioned preparation embodiment 2A, the crude product that obtains is through silica gel column chromatography (sherwood oil: ethyl acetate=4: 1), get 0.8g white solid (2S)-3-(3-bromo-4-hydroxyl-phenyl)-2-t-butoxycarbonyl amino-methyl propionate, yield 38.6%.
MS[M]+＝374.4m/e；
1H-NMR(400MHz，DMSO-d 6)δ7.37(d，1H)，7.10-7.05(dd，2H)，3.56(s，3H)，3.52-2.50(m，1H)，2.80-2.65(m，2H)，1.45(s，9H)。
Preparation embodiment 3A:(2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate (intermediate 3A)
With intermediate 1 (10.1g, 0.05mol), intermediate 2 (14.7g, 0.05mol), triphenyl phosphorus (14.41g 0.055mol) is dissolved in exsiccant tetrahydrofuran (THF) (180mL), drip the toluene solution contain 40%DIAD (74mL, 0.14mmol).Stirring at room 20 hours.Concentrate, residue is through purification by silica gel column chromatography (sherwood oil: ethyl acetate=3: 1), get the light yellow oily of 16.8g (2S)-2-t-butoxycarbonyl amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate, yield 67%.
With (2S)-2-t-butoxycarbonyl amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate (16.8g, 0.035mol), trifluoroacetic acid (34mL), methylene dichloride (340mL) mixed room temperature stir and spend the night.Transfer pH value to neutral with 0.5% aqueous sodium hydroxide solution, the organic layer anhydrous sodium sulfate drying.Concentrate, residue through purification by silica gel column chromatography (chloroform: methyl alcohol=80: 1), 10.6g light brown oily (2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl-methyl propionate, yield 80%.
MS[M]+＝380.4m/e；
1H-NMR(400MHz，DMSO-d 6)δ7.92-7.89(m，2H)，7.52-7.45(m，3H)，7.07(d，2H)，6.83(d，2H)，4.17(t，2H)，3.56(s，3H)，3.51-3.42(m，1H)，2.93(t，2H)，2.80-2.67(m，2H)，2.36(s，3H)，1.75(s，2H)。
Preparation embodiment 3B:(2S)-2-amino-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate (intermediate 3B)
According to preparation intermediate 3A similar methods, substitute intermediate 2A with intermediate 2B, obtain (2S)-2-amino-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl-methyl propionate.
MS[M]+＝459.4m/e；
1H-NMR(400MHz，DMSO-d 6)δ7.92-7.89(m，2H)，7.52-7.48(m，3H)，7.37(d，1H)，7.10-7.05(dd，2H)，4.25(t，2H)，3.56(s，3H)，3.52-2.50(m，1H)，2.94(t，2H)，2.80-2.65(m，2H)，2.38(s，3H)，1.76(s，2H)。
Embodiment 1:(2S)-2-[3-(4-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
(0.38g is 2.11mmol) with thionyl chloride 2mL mixing backflow 3h for 3-(4-methoxyl group-phenyl)-propionic acid.Steam and remove thionyl chloride, residue dissolves with the 4mL methylene dichloride.In another reaction flask, (0.8g, 2.11mmol), (0.23g 2.32mmol) is dissolved in the 5mL methylene dichloride triethylamine, drips above-mentioned solution with intermediate 3A.Drip and finish stirred overnight at room temperature.Concentrate, crude product separates (sherwood oil: ethyl acetate=3: 1) through silica gel column chromatography, get white solid (2S)-2-[3-(4-methoxyl group-phenyl)-propionamido 3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate (0.34g, 30%).
With (2S)-2-[3-(4-methoxyl group-phenyl)-propionamido 3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-methyl propionate is dissolved among the 5mLTHF, adds the 2mL1N lithium hydroxide solution, stirring at room 2h.Adding 2N hydrochloric acid in reaction solution transfers pH value to acid.CHCl 3Extraction, the organic layer drying.Filter, concentrate, get white solid (280mg, 85%).mp：158-159℃。
MS[M] +＝528.1m/e，
1H-NMR(400MHz，DMSO-d 6)δ8.12(d，1H，J＝7.8Hz)，7.92-7.90(m，2H)，7.51-7.48(m，3H)，7.07-7.03(m，4H)，6.83-6.80(m，4H)，4.38-4.35(m，1H)，4.15(t，2H，J＝6.4Hz)，3.69(s，3H)，2.96-2.89(m，3H)，2.79-2.73(m，1H)，2.63(t，2H，J＝7.5Hz)，2.35-2.30(m，5H)。
Embodiment 2:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid
According to method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 3-phenyl-butyric acid-Ji, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid, mp:160-161 ℃.
MS[M+H]+＝512.1m/e。
1HNMR(400MHz，DMSO)δ8.18-8.13(m，1H)，7.91-7.89(m，2H)，7.51-7.45(m，3H)，7.26-7.10(m，6H)，7.11-7.02(d，1H，J＝8.8Hz)，6.88-6.79(m，2H)，4.38-4.33(m，1H)，4.16(t，2H，J＝6.6Hz)，3.06-2.89(m，4H)，2.78-2.69(m，1H)，2.35-2.30(m，5H)，1.07(d，1H，J＝8.0Hz)，0.98(d，1H，J＝8.0Hz)。
Embodiment 3:(2S)-2-[3-(3-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
According to method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 3-(3-methoxyl group-phenyl)-propionic acid, get white solid (2S)-2-[3-(3-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:178-180 ℃.
MS[M]+＝528.1m/e。
1H-NMR(400MHz，DMSO-d 6)δ8.00(d，1H，J＝8.1Hz)，7.91-7.89(m，2H)，7.51-7.45(m，3H)，7.14-7.06(m，3H)，6.82-6.80(m，2H)，6.72-6.71(m，3H)，4.40-4.36(m，1H)，4.16(t，2H，J＝6.5Hz)，3.70(s，3H)，2.96-2.89(m，3H)，2.80-2.68(m，3H)，2.38-2.34(m，5H)。
Embodiment 4:(2S)-2-[3-(2-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 3-(2-methoxyl group-phenyl)-propionic acid, get white solid (2S)-2-[3-(2-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:178-179 ℃.
MS[M]+＝528.1m/e。
1H-NMR(400MHz，DMSO-d 6)δ8.00(d，1H，J＝8.1Hz)，7.91-7.89(m，2H)，7.51-7.45(m，3H)，7.14-7.06(m，3H)，6.82-6.80(m，2H)，6.72-6.71(m，3H)，4.40-4.36(m，1H)，4.16(t，2H，J＝6.5Hz)，3.70(s，3H)，2.96-2.89(m，3H)，2.80-2.68(m，3H)，2.38-2.34(m，5H)。
Embodiment 5:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 3-(4-trifluoromethyl-phenyl)-propionic acid, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid, mp:159-161 ℃.
MS[M]+＝566.1m/e。
1H-NMR(400MHz，DMSO-d 6)δ7.89(d，2H)，7.57-7.48(m，5H)，7.47(d，2H)，7.33(d，2H)，6.75(d，2H)，4.30-4.29(m，1H)，4.13(t，2H，J＝6.0)，2.91-2.81(m，6H)，2.40-2.34(m，5H)。
Embodiment 6:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-methyl-3-phenyl-propionic acid, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid, mp:130-131 ℃.
MS[M]+＝512m/e。
1H-NMR(400MHz，DMSO-d6)δ7.91-7.89(m，2H)，7.52-7.49(m，3H)，7.24-7.02(m，4H)，6.89(d，1H，J＝8.5Hz)，6.77-6.68(m，2H)，4.14-4.11(m，4H)，3.04-2.89(m，5H)，2.54-2.52(m，1H)，2.46-2.38(m，1H)，2.34(s，3H)，0.80(q，3H，J＝6.6Hz)。
Embodiment 7:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-3-(phenyl-propionamido)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 3-phenyl-propionic acid (available from Beijing chemical reagents corporation), get (2S)-3-{4-[2-(5-methyl-2-phenyl-1 of white solid, 3-oxazole-4-yl)-oxyethyl group]-phenyl }-3-(phenyl-propionamido)-propionic acid, mp:167-168 ℃.
MS[M]+＝498.2m/e。
1H-NMR(400MHz，DMSO-d6)δ8.15(d，1H，J＝8.1Hz)，7.92-7.90(m，2H)，7.50-7.48(m，3H)，7.22-7.13(m，2H)，7.13-7.07(m，5H)，6.81(d，2H，J＝8.4Hz)，4.37-4.35(m，1H)，4.15(t，2H，J＝6.5Hz)，3.59(t，1H，J＝6.5Hz)，2.93-2.89(m，3H)，2.73-2.69(m，2H)，2.38-2.35(m，5H)。
Embodiment 8:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-pentafluorophenyl group-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-pentafluorophenyl group)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-pentafluorophenyl group-kharophen)-propionic acid, mp:198-199 ℃.
MS[M]+＝574.3m/e。
1H-NMR(400MHz，DMSO-d6)δ12.69(brs，1H)，8.45(d，1H，J＝8.1Hz)，7.92-7.90(m，2H)，7.50-7.47(m，3H)，7.11-7.09(d，2H，J＝8.6Hz)，6.83-6.82(d，2H，J＝8.6Hz)，4.35(m，1H)，4.18(t，2H，J＝6.7Hz)，3.60-2.81(m，4H)，2.35(s，3H)。
Embodiment 9:(2S)-2-[2-(2-methoxyl group-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-methoxyl group-phenyl)-acetate, get white solid (2S)-2-[2-(2-methoxyl group-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:165-166 ℃.
MS[M]+＝514.3m/e。
1H-NMR(400MHz，DMSO-d6)δ12.50(brs，1H)，7.91-7.90(m，3H)，7.50-7.46(m，3H)，7.15-7.06(m，3H)，6.97-6.96(m，1H)，6.86-6.75(m，4H)，4.40(m，1H)，4.17(t，2H，J＝6.4Hz)，3.65(s，3H)，3.35(s，2H)，2.99-2.91(m，3H)，2.89-2.76(m，1H)，2.35(s，3H)。
Embodiment 10:(2S)-2-[2-(2-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-chloro-phenyl)-acetate (available from Beijing chemical reagents corporation), get white solid (2S)-2-[2-(2-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:188-189 ℃.
MS[M]+＝518.3m/e。
1H-NMR(400MHz，DMSO-d6)δ12.64(brs，1H)，8.27(d，1H，J＝8.2Hz)，7.93-7.90(m，2H)，7.51-7.47(m，3H)，7.34-7.32(m，5H)，6.84-6.81(m，2H)，4.42-4.39(m，1H)，4.18-4.17(t，2H，J＝6.6Hz)，3.55-2.77(m，4H)，2.36(s，3H)。
Embodiment 11:(2S)-2-[2-(4-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(4-chloro-phenyl)-acetate (available from Beijing chemical reagents corporation), get white solid (2S)-2-[2-(4-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:168-170 ℃.
MS[M]+＝518.2m/e。
1H-NMR(400MHz，DMSO-d6)δ8.28(d，1H，J＝8.0Hz)，7.90(m，2H)，7.52-7.47(m，3H)，7.28-7.25(m，2H)，7.13-7.05(m，6H)，6.80-6.78(d，2H，J＝8.6Hz)，4.37(m，1H)，4.16(t，2H，J＝6.6Hz)，3.01-2.75(m，4H)，2.35(s，3H)。
Embodiment 12:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-neighbour-trifluoromethyl-phenyl-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-neighbour-trifluoromethyl-phenyl)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-neighbour-trifluoromethyl-phenyl-kharophen)-propionic acid, mp:154-156 ℃.
MS[M] +＝552.2m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.67(brs，1H)，8.41(d，1H，J＝8.8Hz)，7.93-7.89(m，2H)，7.62-7.35(m，4H)，7.21-7.12(m，3H)，6.86-6.84(m，2H)，4.40(m，1H)，4.17(t，2H)，3.03-2.76(m，4H)，2.37(s，3H)。
Embodiment 13:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-right-trifluoromethyl-phenyl-kharophen)-propionic acid
Adopt preparation method similar to Example 1, wherein 3-(4-methoxyl group-phenyl)-propionic acid is replaced with 2-(2-right-trifluoromethyl-phenyl)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-right-trifluoromethyl-phenyl-kharophen)-propionic acid, mp:169-170 ℃.
MS[M] +＝552.2m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.78(brs，1H)，8.45(d，1H，J＝8.2Hz)，7.91-7.90(m，2H)，7.58-7.47(m，5H)，7.34-7.32(d，2H，J＝8.8Hz)，7.09-7.06(d，2H，J＝8.5Hz)，4.37(m，1H)，4.16(t，2H，J＝6.6Hz)，3.50(q，2H)，3.01-2.75(m.4H)，2.36(s，3H)。
Embodiment 14:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(3-trifluoromethyl-phenyl)-kharophen]-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(3-trifluoromethyl-phenyl)-acetate, white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl-2-[2-(3-trifluoromethyl-phenyl)-kharophen]-propionic acid mp:172-173 ℃.
MS[M] +＝552.2m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.59(brs，1H)，8.39(d，1H，J＝8.1Hz)，7.93-7.90(m，2H)，7.55-7.36(m，7H)，7.07-7.05(d，2H)，6.78-6.76(d，2H，J＝8.7Hz)，4.38(m，1H)，4.17(t，3H，J＝6.6Hz)，3.52(m，2H)，3.01-2.77(m，4H)，2.36(s，3H)。
Embodiment 15:(2S)-2-[2-(2,3-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2,3-two fluoro-phenyl)-acetate, get white solid (2S)-2-[2-(2,3-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:179-180 ℃.
MS[M] +＝520.2m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.60(brs，1H)，8.34(d，1H，J＝8.1Hz)，7.93-7.90(m，2H)，7.51-7.47(m，3H)，7.22-6.95(m，5H)，6.89-6.81(d，1H)，4.38(m，1H)，4.18(t，2H，J＝6.6Hz)，2.51(s，2H)，3.02-2.77(m，4H)，2.36(s，3H)。
Embodiment 16:(2S)-2-[2-(3,4-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(3,4-two fluoro-phenyl)-acetate, get white solid (2S)-2-[2-(3,4-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:172-173 ℃.
MS[M] +＝520.3m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.71(brs，1H)，8.26(d，1H，J＝8.3Hz)，7.92-7.90(m，2H)，7.52-7.46(m，3H)，7.30-7.14(m，2H)，7.07-7.05(d，1H，J＝8.60Hz)，6.97-6.77(d，2H，J＝8.8Hz)，4.37-4.34(m，1H)，4.16(t，2H，J＝6.6Hz)，3.41(q，2H，J＝4.3Hz)，3.01-2.89(m，3H)，2.81-2.75(m，1H)，2.35(s，3H)。
Embodiment 17:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl-acetylaminohydroxyphenylarsonic acid propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-phenyl-acetic acid (available from Beijing chemical reagents corporation), get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl-acetylaminohydroxyphenylarsonic acid propionic acid, mp:137-138 ℃.
MS[M] +＝484.3m/e。
1H-NMR(400MHz，DMSO-d 6)δ8.23(d，1H，J＝8.2Hz)，7.91(m，2H)，7.48(m，2H)，7.21-7.07(m，2H)，6.79(m，2H)，4.37(m，1H)，4.18(t，2H，J＝6.6Hz)，3.38(m，2H)，3.03-2.90(m，3H)，2.80(m，1H)，2.36(s，3H)。
Embodiment 18:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-is to tolyloxy-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-is to tolyloxy)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-is to tolyloxy-kharophen)-propionic acid, mp:163-164 ℃.
MS[M] +＝514.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.65(brs，1H)，8.06(d，1H，J＝8.2Hz)，7.92-7.90(m，2H)，7.52-7.45(m，3H)，7.10-7.03(m，4H)，6.82-6.73(m，4H)，4.49-4.36(m，3H)，4.18(t，2H，J＝6.6Hz)，3.05-3.00(m，1H)，2.93-2.87(m，3H)，2.35(s，3H)，2.21(s，3H)。
Embodiment 19:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-1-base oxygen base)-kharophen]-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-[2-(naphthalene-1-base oxygen base)]-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-1-base oxygen base)-kharophen]-propionic acid, mp:124-126 ℃.
MS[M] +＝550.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ8.17(m，2H)，7.93-7.81(m，3H)，7.51-7.45(m，6H)，7.36-7.29(m，1H)，7.13-7.10(m，2H)，6.81-6.75(m，3H)，4.76-4.65(m，2H)，4.56-4.52(m，1H)，4.21(t，2H，J＝6.6Hz)，3.09-2.89(m，4H)，2.35(s，3H)，2.14(s，3H)。
Embodiment 20:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-nitro-phenoxy group)-kharophen]-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-nitro-phenoxy group)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-nitro-phenoxy group)-kharophen]-propionic acid, mp:184-186 ℃.
MS[M] +＝545.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.81(brs，1H)，8.10(d，1H，J＝8.2Hz)，7.92-7.90(m，3H)，7.56-7.45(m，4H)，7.12-7.03(m，4H)，6.83-6.82(m，2H)，4.70(s，2H)，4.47(m，1H)，4.16(t，2H，J＝6.6Hz)，3.06-2.76(m.4H)，2.36(s，3H)。
Embodiment 21:(2S)-2-[2-(3-methoxyl group-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(3-methoxyl group-phenoxy group)-acetate, get white solid (2S)-2-[2-(3-methoxyl group-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:137-138 ℃.
MS[M] +＝530.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.80(brs，1H)，8.10(d，1H，J＝8.0Hz)，7.92-7.90(m，2H)，7.51-7.47(m，3H)，7.15-7.07(m，3H)，6.81-6.79(d，2H，J＝8.5Hz)，6.53-6.41(m，3H)，4.43(m，1H)，4.16(t，2H，J＝6.6Hz)，3.70(s，3H)，3.04-2.90(m，4H)，2.35(s，3H)。
Embodiment 22:(2S)-2-[2-(4-fluoro-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(4-fluoro-phenoxy group)-acetate, get white solid (2S)-2-[2-(4-fluoro-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:132-134 ℃.
MS[M] +＝518.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.60(brs，1H)，8.06(d，1H，J＝8.2Hz)，7.91-7.89(m，2H)，7.51-7.46(m，3H)，7.10-7.04(m，4?H)，6.89-6.80(m，4H)，4.50-4.43(m，3H)，4.19-4.16(t，2H，J＝6.6Hz)，3.06-2.87(m，4Hz)，2.34(s，3H)。
Embodiment 23:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-phenoxy group-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-phenoxy group-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-phenoxy group-kharophen)-propionic acid, mp:114-116 ℃.
MS[M] +＝500.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ8.09(d，1H)，7.89(m，2H)，7.47(m，3H)，7.26-7.20(m，2H)，7.10(d，2H)，6.90-6.80(m，5H)，4.48-4.44(m，3H)，4.16(t，2H，J＝6.6Hz)，3.08-2.85(m，4H)，2.35(s，3H)。
Embodiment 24:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(4-nitro-phenoxy group-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(4-nitro-phenoxy group)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(4-nitro-phenoxy group-kharophen)-propionic acid, mp:181-182 ℃.
MS[M] +＝545.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ8.36(d，1H，J＝8.2Hz)，8.16-8.14(d，2H)，7.91-7.89(m，2H)，7.51-7.46(m，3H)，7.10(d，2H)，7.01(d，2H，J＝9.2Hz)，7.00-6.80(d，2H)，4.65(s，2H)，4.46(m，1H)，4.15(t，2H，J＝6.6Hz)，3.08-2.93(m，3H)，2.35(s，3H)。
Embodiment 25:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(2-oxy-o-cresyl)-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid, mp:192-194 ℃.
MS[M] +＝514.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.87(brs，1H)，7.96-7.90(m，3H)，7.50-7.48(m，3H)，7.10-7.03(m，4H)，6.84-6.81(m，3H)，6.71-6.69(m，1H)，4.51-4.41(m，3H)，4.19-4.16(t，2H，J＝6.6Hz)，3.06-2.90(m，4H)，2.35(s，3H)，2.13(s，3H)。
Embodiment 26:(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-2-base oxygen)-kharophen]-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-[2-(naphthalene-2-base oxygen)]-acetate, get white solid (2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-2-base oxygen)-kharophen]-propionic acid, mp:183-185 ℃.
MS[M] +＝550.4m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.81(brs，1H)，8.22-8.20(d，1H，J＝8.0Hz)，7.93-7.91(d，2H，J＝6.4Hz)，7.84-7.82(d，2H，J＝8.0Hz)，7.74-7.72(d，2H，J＝8.0Hz)，7.51-7.43(m，4H)，7.36-7.32(t，1H)，7.22-7.20(d，2H，J＝8.8Hz)，7.10-7.08(d，2H，J＝8.4Hz)，6.79-6.73(d，2H，J＝8.4Hz)，4.61(s，2H)，4.51(m，1H)，4.12(t，2H，J＝6.6Hz)，3.07-2.89(m，4H)，2.35(s，3H)。
Embodiment 27:(2S)-2-[2-(4-chloro-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(4-chloro-thiophenyl)-acetate, get white solid (2S)-2-[2-(4-chloro-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:164-166 ℃.
MS[M] +＝550.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ8.03(d，1H)，7.91-7.90(m，2H)，7.49-7.48(m，3H)，7.30-7.27(m，4H)，7.02-7.00(d，2H，J＝8.8Hz)，6.75-6.73(d，2H，J＝8.2Hz)，4.20-4.13(m，3H)，3.01-2.81(m，4H)，2.35(s，3H)。
Embodiment 28:(2S)-2-[2-(4-methoxyl group-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(4-methoxyl group-thiophenyl)-acetate, get white solid (2S)-2-[2-(4-methoxyl group-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:156-158 ℃.
MS[M] +＝546.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.71(brs，1H)，8.28(d，1H，J＝8.0Hz)，7.92-7.90(m，2H)，7.52-7.47(m，3H)，7.17-7.13(m，1H)，7.07-7.05(m，2H)，6.87-6.70(m，5H)，4.71(m，1H)，4.14(m，1H)，3.70(s，3H)，3.65(s，2H)，2.98-2.78(m，4H)，2.35(s，3H)。
Embodiment 29:(2S)-2-[2-(8-chloro-naphthalene-1-base sulfenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid
Adopt preparation method similar to Example 1,3-(4-methoxyl group-phenyl)-propionic acid is wherein replaced with 2-(8-chloro-naphthalene-1-base sulfenyl)-acetate, get white solid (2S)-2-[2-(8-chloro-naphthalene-1-base sulfenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid, mp:138-140 ℃.
MS[M] +＝600.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.70(brs，1H)，8.36(d，1H，J＝8.0Hz)，7.92-7.85(m，3H)，7.72(d，1H，J＝7.8Hz)，7.60(d，1H，J＝7.3Hz)，7.52-7.33(m，6H)，7.06-7.04(d，2H，8.5Hz)，6.75-6.73(d，2H，J＝8.5Hz)，4.43-4.38(m，1H)，4.14(t，2H，J＝6.5Hz)，3.73(s，2H)，2.99-2.79(m，4H)，2.35(s，3H)。
Embodiment 30:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-methoxyl group-phenyl)-kharophen]-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 2-(2-methyl-phenyl)-acetate (available from Beijing chemical reagents corporation), get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-methoxyl group-phenyl)-kharophen]-propionic acid, mp:194-195 ℃.
MS[M] +＝592.2m/e。
1H-NMR(400MHz，DMSO)δ12.76(brs，1H)，8.08(d，1H，J＝8.0Hz)，7.93-7.91(m，2H)，7.53-7.48(m，3H)，7.41-7.40(s，1H)，7.15-7.10(m，2H)，7.03-6.73(m，6H)，4.40(m，1H)，4.25(t，2H，J＝6.6Hz)，3.63(s，3H)，3.35(s，2H)，3.02-2.75(m，4H)，2.39(s，3H)。
Embodiment 31:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl acetylaminohydroxyphenylarsonic acid propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 2-phenyl-acetic acid (available from Beijing chemical reagents corporation), get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl acetylaminohydroxyphenylarsonic acid propionic acid, mp:189-190 ℃.
MS[M] +＝563.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.74(brs，1H)，8.20(d，1H，J＝8.0)，7.93(m，2H)，7.52-7.46(m，3H)，7.40-7.39(m，1H)，7.20-7.07(m，6H)，6.99-6.97(d，1H，J＝8.5Hz)，4.38-4.33(m，1H)，4.25(t，2H，J＝6.3Hz)，3.41(q，2H)，3.02-2.93(m，3H)，2.80-2.75(m，1H)，2.38(s，3H)。
Embodiment 32:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-methoxyl group-phenyl)-propionamido]-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with (4-methoxyl group-phenyl) propionic acid, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-methoxyl group-phenyl) propionamido]-propionic acid, mp:195-196 ℃.
MS[M] +＝608.0m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.60(s，1H)，8.08(d，1H，J＝7.9Hz)，7.91-7.90(m，2H)，7.50-7.46(m，3H)，7.40(s，1H，J＝2.0Hz)，7.13-7.11(m，1H)，7.02(d，3H，J＝7.3Hz)，6.77(d，2H，J＝8.8Hz)，4.41-4.35(m，1H)，4.25(t，2H，J＝6.2Hz)，3.70(s，3H)，2.99-2.92(m，3H)，2.78-2.73(m，1H)，2.67(t，2H，J＝7.6Hz)，2.36-2.29(m，5H)。
Embodiment 33:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-(3-phenyl-propionamido)-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 3-phenyl-propionic acid (available from Beijing chemical reagents corporation), get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-(3-phenyl-propionamido)-propionic acid, mp:190-191 ℃.
MS[M] +＝578.0m/e。
1H-NMR(400MHz，DMSO-d 6)δ8.15(d，1H，J＝8.1Hz)，7.92-7.90(m，2H)，7.50-7.48(m，3H)，7.22-7.13(m，2H)，7.13-7.07(m，5H)，6.81(d，2H，J＝8.4Hz)，4.37-4.35(m，1H)，4.15(t，2H，J＝6.5Hz)，3.59(t，1H，J＝6.5Hz)，2.93-2.89(m，3H)，2.73-2.69(m，2H)，2.38-2.35(m，5H)。
Embodiment 34:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(2-methoxyl group-phenyl)-propionamido]-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 3-(2-methoxyl group-phenyl)-propionic acid, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(2-methoxyl group-phenyl)-propionamido]-propionic acid, mp:178-180 ℃.
MS[M] +＝608.0m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.60(s，1H)，8.05(d，1H，J＝8.0Hz)，7.91-7.89(m，2H)，7.51-7.46(m，3H)，7.41-7.39(m，1H)，7.17-7.00(m，4H)，6.92-6.90(m，1H)，6.80-6.77(m，1H)，4.40-4.34(m，1H)，4.23(t，2H，J＝6.3Hz)，3.74(s，3H)，2.98-2.92(m，3H)，2.79-2.64(m，3H)，2.36-2.28(m，5H)。
Embodiment 35:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(3-methoxyl group-phenyl)-propionamido]-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 3-(3-methoxyl group-phenyl)-propionic acid, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(3-methoxyl group-phenyl)-propionamido]-propionic acid, mp:195-196 ℃.
MS[M] +＝608.0m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.62(s，1H)，8.01(d，1H，J＝8.0Hz)，7.91-7.89(m，2H)，7.51-7.46(m，3H)，7.40(d，1H，J＝2.0Hz)，7.14-7.10(m，2H)，7.01(d，1H，J＝8.5Hz)，6.72-6.68(m，3H)，4.41-4.36(m，1H)，4.23(t，2H，J＝6.5Hz)，3.69(s，3H)，2.86-2.92(m，3H)，3.00-2.92(m，3H)，2.79-2.67(m，3H)，2.37-2.33(m，5H)。
Embodiment 36:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 3-(4-trifluoromethyl-phenyl)-propionic acid (available from Aldrich company), get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid, mp:214-216 ℃.
MS[M] +＝646.0m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.74(s，1H)，8.20(d，1H，J＝8.1Hz)，7.91-7.89(m，2H)，7.56(d，2H，J＝7.9Hz)，7.51-7.47(m，3H)，7.40(d，1H，J＝2.0Hz)，7.33(d，2H，J＝7.9Hz)，7.13-7.11(m，H)，7.02(d，1H，J＝8.5Hz)，4.40-4.34(m，1H)，4.22(t，2H，J＝6.5Hz)，2.95-2.92(m，3H)，2.81-2.79(m，3H)，2.40-2.37(m，5H)。
Embodiment 37:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 2-methyl-3-phenyl-propionic acid, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid, mp:164-166 ℃.
MS[M] +＝592.1m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.66(s，1H)，8.00(d，1H，J＝8.0Hz)，7.91-7.89(m，2H)，7.50-7.47(m，3H)，7.40-7.36(m，H)，7.23-6.97(m，7H)，4.37-4.35(m，1H)，4.22(t，2H，J＝6.3Hz)，3.01-2.89(m，3H)，2.86-2.75(m，2H)，2.44-2.36(m，5H)，0.92-0.82(m，3H)。
Embodiment 38:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 3-phenyl-butyric acid, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid, mp:165-167 ℃.
MS[M] +＝592.0m/e。
1H-NMR(400MHz，DMSO-d 6)δ12.57(s，1H)，8.11-8.08(m，1H)，7.91-7.88(m，2H)，7.50-7.46(m，3H)，7.43-7.38(m，1H)，7.25-7.21(m，2H)，7.16-6.98(m，5H)，4.38-4.35(m，1H)，4.23(m，2H)，3.06-2.89(m，4H)，2.78-2.72(m，1H)，2.36-2.23(m，5H)，1.07-0.98(m，3H)。
Embodiment 39:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 2-(2-oxy-o-cresyl)-acetate, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid, 204 ℃ of mp:202.
MS[M] +＝593.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ12.85(brs，1H)，7.97-7.89(m，3H)，7.49-7.40(m，3H)，7.15-6.99(m，4H)，6.83-6.79(m，1H)，6.70-6.68(d，1H，J＝8.1Hz)，4.50-4.39(m，3H)，4.26-4.23(t，2H，J＝6.6Hz)，3.05-2.92(m，4H)，2.37(s，3H)，2.13(s，3H)。
Embodiment 40:(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-thiophenyl-kharophen)-propionic acid
Adopt preparation method similar to Example 1, intermediate 3A is wherein replaced with intermediate 3B, 3-(4-methoxyl group-phenyl)-propionic acid replaces with 2-(2-thiophenyl)-acetate, get white solid (2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-thiophenyl-kharophen)-propionic acid, mp:171-173 ℃.
MS[M] +＝595.2m/e，
1H-NMR(400MHz，DMSO-d 6)δ7.91-7.90(m，2H)，7.50-7.38(m，4H)，7.27-7.08(m，6H)，6.97-6.95(d，1H，J＝8.2Hz)，4.35(m，1H)，4.23(t，2H，J＝6.6Hz)，3.61(m，2H)，3.01-2.93(m，3H)，3.01-2.93(m，3H)，2.82-2.78(m，1H)，2.38(s，3H)。
Embodiment 41: activate the determination of activity of people PPAR α and PPAR γ
Functional effect to compound transient transfection in the 293-T cell screens, and activates the ability of PPAR hypotype to measure them.Adopt and set up of the influence of Chimerical receptor systematic comparison receptor subtype in advance, reduce the endogenous influence as interior mark with Rluc to identical target gene transcriptional activity.People PPAR α and PPAR γ ligand binding domain are combined the territory with yeast transcription factor GAL4DNA separately to be merged.Be connected on the mammiferous expression vector pM, make up pM-hPPAR α/GAL4 and two kinds of plasmids of pM-PPAR γ/GAL4.The GAL4DNA land is connected with pB4-tk-luc, constitutes pB4-RES-tk-luc (reporter gene that contains the Photinus pyralis LUC of GAL4DNA binding site).Influence as positive transfection efficiency of interior calibration and endogenous with pRL-CMV-Rluc.
The 293-T cell inoculation is gone into 48 orifice plates, and cell density is 2-4 * 10 4Individual/hole, nutrient solution is 1640 substratum of the no phenol red antibiotic-free of 10% degreasing foetal calf serum (FCS).After 48 hours, nutrient solution is replaced by 1640 substratum of the no phenol red antibiotic-free of 5% degreasing FCS, then respectively the pM-hPPAR/GAL4 of two kinds of hypotypes, pB4-RES-tk-luc and three kinds of plasmid cotransfections of pRL-CMV-Rluc in the 293-T cell, administration after 24 hours, the intensity of 24 hours detection luciferases after the administration.With 0.2 ‰ DMSO as blank.
The part The compounds of this invention is to agonism (10 μ M) and the EC thereof of PPAR α 50
Compound Number of photons (* 10 4) Compare the multiple of growth with control group ??EC 50(μM)
Comparative examples 3 embodiment 6 embodiment 7 embodiment 8 embodiment 9 embodiment 10 embodiment 11 embodiment 14 embodiment 15 embodiment 20 embodiment 23 embodiment 24 embodiment 25 embodiment 26 embodiment 28 ????2.1 ????7.4? ????17.2 ????30 ????8.2 ????26.9 ????23.1 ????21.7 ????6.4 ????23.8 ????9.9 ????17.5 ????19.9 ????16.4 ????12.1 ????4.6 ? ????3.5? ????8.2 ????14.3 ????3.9 ????12.8 ????11 ????10.3 ????3 ????11.3 ????4.7 ????8.3 ????9.5 ????7.8 ????5.8 ????2.2 ? ? ????9.15? ? ????9.01 ????10.45 ????11.51
The part The compounds of this invention is to agonism (10 μ M) and the EC thereof of PPAR γ 50
Compound Number of photons (* 10 4) Compare the multiple of growth with control group EC 50(μM)
Comparative examples 3 embodiment 6 embodiment 7 embodiment 8 embodiment 9 embodiment 10 embodiment 11 embodiment 14 embodiment 15 embodiment 20 embodiment 23 embodiment 24 embodiment 25 embodiment 26 embodiment 28 ????1.4 ????2.1 ????23.9 ????11.8 ????12.2 ????12.4 ????6.2 ????13.7 ????- ????11.9 ????20 ????4.1 ????4.1 ????12.5 ????16.2 ????18.1 ? ????1.5 ????17.1 ????8.4 ????8.7 ????8.9 ????4.4 ????9.8 ????- ????8.5 ????14.3 ????2.9 ????2.9 ????8.9 ????11.6 ????12.9 ? ? ????0.058? ? ????1.19 ????0.021 ????0.24

Claims (10)

1. general formula (I) compound, its raceme, optically active isomer or its pharmacy acceptable salt or solvate,
Figure A2004100425720002C1
Wherein:
R 1And R 2Be selected from H independently of one another, C 1-C 4The straight or branched alkyl;
Ar is selected from aromatic carbocyclic or heterocycle, and ring wherein can be monocycle, dicyclo or three rings; Each ring is 5-6 unit ring, comprises in the heterocycle that 1-4 is selected from following heteroatoms: O, S, N; Do not have on the ring to replace or be selected from following substituting group and replace: halogen, nitro, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, C by 1-5 1-C 6The straight or branched alkyl, C 2-C 6The straight or branched thiazolinyl, C 1-C 4Alkoxyl group, C 2-C 4Alkenyloxy, phenoxy group, benzyloxy, carboxyl or amino;
Y is H, halogen;
N is the integer of 1-4;
M is 0 or 1,
X is CH 2, O, S, Group.
2. the compound of claim 1, the S configurational isomer that it is represented for general formula I I,
Figure A2004100425720003C1
Wherein:
Be connected in COOR 1Carbon atom be the S configuration;
R 1And R 2Be selected from H independently of one another, CH 3
Ar is selected from aromatic carbocyclic or heterocycle, and ring wherein can be monocycle, dicyclo or three rings; Each ring is 5-6 unit ring, comprises in the heterocycle that 1-4 is selected from following heteroatoms: O, S, N; Do not have on the ring to replace or be selected from following substituting group and replace: halogen, nitro, hydroxyl, methylol, trifluoromethyl, trifluoromethoxy, C by 1-5 1-C 6The straight or branched alkyl, C 2-C 6The straight or branched thiazolinyl, C 1-C 4Alkoxyl group, C 2-C 4Alkenyloxy, phenoxy group, benzyloxy, carboxyl or amino;
Y is H, Br;
N is the integer of 1-4;
M is 0 or 1,
X is CH 2, O, S,
Figure A2004100425720003C2
Group,
Or its pharmacy acceptable salt or solvate.
3. claim 1 or 2 compound, it is selected from:
(2S)-2-[3-(4-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid;
(2S)-2-[3-(3-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[3-(2-methoxyl group-phenyl)-propionamido]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-3-phenyl propionamido)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-pentafluorophenyl group-kharophen)-propionic acid;
(2S)-2-[2-(2-methoxyl group-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(2-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(4-chloro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-neighbour-trifluoromethyl-phenyl-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-right-trifluoromethyl-phenyl-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(3-trifluoromethyl-phenyl)-kharophen]-propionic acid;
(2S)-2-[2-(2,3-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(3,4-two fluoro-phenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl-acetylaminohydroxyphenylarsonic acid propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-is to tolyloxy-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-1-base oxygen base)-kharophen]-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-nitro-phenoxy group)-kharophen]-propionic acid;
(2S)-2-[2-(3-methoxyl group-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(4-fluoro-phenoxy group)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-phenoxy group-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(4-nitro-phenoxy group-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid;
(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(naphthalene-2-base oxygen)-kharophen]-propionic acid;
(2S)-2-[2-(4-chloro-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(4-methoxyl group-thiophenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-2-[2-(8-chloro-naphthalene-1-base sulfenyl)-kharophen]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[2-(2-methoxyl group-phenyl)-kharophen]-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-phenyl acetylaminohydroxyphenylarsonic acid propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-methoxyl group-phenyl)-propionamido]-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-(3-phenyl-propionamido)-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(2-methoxyl group-phenyl)-propionamido]-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(3-methoxyl group-phenyl)-propionamido]-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-[3-(4-trifluoromethyl-phenyl)-propionamido]-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-methyl-3-phenyl-propionamido)-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(3-phenyl-butyrylamino)-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-oxy-o-cresyl-kharophen)-propionic acid;
(2S)-3-{3-bromo-4-[2-(5-methyl-2-phenyl-1,3-oxazole-4-yl)-oxyethyl group]-phenyl }-2-(2-thiophenyl-kharophen)-propionic acid;
Or its pharmacy acceptable salt or solvate.
4. pharmaceutical composition, it contains the arbitrary compound of claim 1-3, its raceme, optically active isomer or its pharmacy acceptable salt or solvate and at least a pharmaceutically acceptable carrier.
5. the preparation method of the described compound of claim 1, it comprises:
Make the formula III compound
Y wherein, n, R 1Definition with claim 1;
React with formula X compound,
Ar wherein, X, R 2, the definition of m is with claim 1;
Obtain compound of Formula I,
R wherein 1, R 2, Ar, X, Y, the definition of m and n is with claim 1.
6. the method for claim 5, formula III compound wherein can prepare by the following method:
1) formula IV compound and benzamide are reacted, cyclization obtains formula V compound, and formula V compound obtains formula VI compound again through tetrahydrochysene lithium aluminium reducing;
2) definition that makes wherein Y and n with the formula VII compound of claim 1 earlier with R wherein 1Definition is with the R of general formula I 1OH and thionyl chloride reaction are followed and BOC 2O reacts, and obtains the compound of VIII, wherein Y, n and R 1Definition with claim 1;
3) the formula VIII compound reaction that formula VI compound and the step 2 that step 1) is obtained) obtains obtains wherein Y, n and R 1Definition is with the formula IX compound of claim 1,
Then make formula IX compound with trifluoroacetic acid deprotection base, obtain wherein Y, n and R 1Definition with the formula III compound of claim 1,
7. the described method of claim 5, it further comprises:
Make wherein R 1=C 1-C 4The compound of Formula I of straight or branched alkyl and alkali metal hydroxide reaction obtain R 1The compound of Formula I of=H.
8. the compound of claim 1 is used to prepare the purposes of the medicine of disease, risk factor or the illness for the treatment of hPPAR α and hPPAR γ mediation.
9. the purposes of claim 8, wherein said disease, risk factor or illness are that hyperglycemia, lipoidosis lipidemia or type ii diabetes comprise relevant diabetic lipoidosis lipidemia.
10. formula III compound
Figure A2004100425720008C3
Y wherein, n, R 1Definition with claim 1.
CNB2004100425722A 2004-05-24 2004-05-24 Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist Expired - Fee Related CN100436430C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNB2004100425722A CN100436430C (en) 2004-05-24 2004-05-24 Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist
PCT/CN2005/000147 WO2005115998A1 (en) 2004-05-24 2005-02-02 TYROSINE DERIVATIVES SUBSTITUTED BY ALKANOYLAS hPPARα & hPPARϜ ANGONISTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100425722A CN100436430C (en) 2004-05-24 2004-05-24 Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist

Publications (2)

Publication Number Publication Date
CN1702068A true CN1702068A (en) 2005-11-30
CN100436430C CN100436430C (en) 2008-11-26

Family

ID=35450816

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100425722A Expired - Fee Related CN100436430C (en) 2004-05-24 2004-05-24 Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist

Country Status (2)

Country Link
CN (1) CN100436430C (en)
WO (1) WO2005115998A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101805308B (en) * 2009-02-13 2011-10-19 天津药物研究院 Compound containing tyrosine and isoxazole skeleton and preparation method and application thereof
CN101805336B (en) * 2009-02-13 2012-05-30 天津药物研究院 Compound containing tryptophane and isoxazole skeleton and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325263A (en) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd New 2-amino-3-phenylpropionic acid derivative
IL121202A (en) * 1996-07-01 2001-08-26 Lilly Co Eli Hypoglycemic and hypolipidemic compounds, process for their preparation, pharmaceutial compositions comprising same, and uses thereof
EE03765B1 (en) * 1996-08-19 2002-06-17 Japan Tobacco Inc. Propionic acid derivatives and their uses
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2000344748A (en) * 1999-03-29 2000-12-12 Welfide Corp 3-aromatic substituted propionic acid or acrylic acid compound
AU7115300A (en) * 1999-09-08 2001-04-10 Glaxo Group Limited Oxazole ppar antagonists
SI1392295T1 (en) * 2001-05-15 2006-10-31 Hoffmann La Roche Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
KR20040030658A (en) * 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 Modulators of peroxisome proliferator activated receptors(ppar)
EP1466909A4 (en) * 2002-01-17 2005-12-07 Toaeiyo Ltd Halogenobenzyl aminopropionic acid derivatives
JP4705756B2 (en) * 2002-02-07 2011-06-22 仁 遠藤 Aromatic amino acid derivatives and pharmaceutical compositions
JP2006513250A (en) * 2003-01-28 2006-04-20 中国科学院上海薬物研究所 Alanine compound, production method and use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101805308B (en) * 2009-02-13 2011-10-19 天津药物研究院 Compound containing tyrosine and isoxazole skeleton and preparation method and application thereof
CN101805336B (en) * 2009-02-13 2012-05-30 天津药物研究院 Compound containing tryptophane and isoxazole skeleton and preparation method and application thereof

Also Published As

Publication number Publication date
CN100436430C (en) 2008-11-26
WO2005115998A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
CN1042532C (en) Novel compounds
CN1184215C (en) Substd. oxazoles and thiazoles derivs. as HPPAR alpha activators
CN1255103C (en) Diaryl cycloalkyl derivatives, the use thereof as PPAR activators and pharmaceutical compositions containing thereof
CN1354742A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR)a
CN101007804B (en) 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses
CN1280575A (en) New tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1638768A (en) Thiazole and oxazole derivatives that modulate PPAR activity
CN1033325C (en) Antiinflammatory hydroxamic acids and N-hydroxyureas
CN1681779A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
CN1738819A (en) 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors
CN1304401A (en) Calcilytic compounds
CN1067052A (en) The diaminophthalimides and the analogue thereof that replace
CN1479716A (en) Propionic acid derivatives with PPAR-alpha activating properties
CN85107496A (en) The method for preparing tetrahydronaphthalenderivatives derivatives
CA2475137C (en) New heterocyclic oxime derivatives, their preparation process and the pharmaceutical compositions that contain them
CN1038582C (en) Benzene derivative useful for ischemic diseases
CN1063443C (en) Novel benzothiazole derivatives
CN1702068A (en) Alkanoyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist
CN1283196A (en) N-pheny lamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them
CN1861560A (en) Carboxylic acid derivant, its preparation process and pharmaceutical composition
CN100344618C (en) N-benzyl acryloyl substituted tyrosine derivatives as hPPAR alpha and hPPAR gamma agonist
CN88102356A (en) 1,3-two  alkanes
CN1798735A (en) 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
CN101076334A (en) Benzoureas having anti-diabetic activity
CN1047857A (en) Alpha-hydroxy-3-phenoxy group propanamine derivatives and manufacturing thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20061215

Address after: Beijing City, Haidian District red No. 44 village of Zizhu Building Room 301

Applicant after: Beijing Muolike Science and Technology Co., Ltd.

Address before: No. 27 Taiping Road, Beijing, Haidian District

Applicant before: Institute of Poisonous Substance and Medicine of Military of Military academy of medical sciences of

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081126

Termination date: 20190524

CF01 Termination of patent right due to non-payment of annual fee